🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "significant breakthrough" in the effort against drug-resistant strains of the bacteria, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are increasing around the world, with estimates suggesting over 82 million infections per year. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune step in the context of rising global incidence, increasing antimicrobial resistance and the highly restricted treatment choices at this time.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The WHO has designated it as a "critical concern". A tracking program revealed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Receive Approval

One new antibiotic, marketed under the name a brand name, was approved by the American regulatory agency in mid-December for combating gonorrhoea. This disease can lead to major issues, including infertility. Experts believe that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in close succession. This medication, which is employed against UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This milestone signifies a huge turning point in the therapy of superbug gonorrhoea, which previously has been staying ahead of medical innovation.”

Research Study Results and Worldwide Availability

Based on data released by a major medical journal, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which combines two antibiotics. The research included nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the authority to make available and distribute the drug in numerous regions with limited resources.

Medical professionals directly involved have voiced optimism. Having a one-pill regimen of this kind is described as a "revolutionary step" for public health efforts. This is deemed vital to lessen the impact of the infection for people and to halt the transmission of untreatable gonorrhoea worldwide.